Ginkgo Bioworks Holdings Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

DNA$12.37+9.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

10. Supplemental Information

Supplemental Information

Cash, Cash Equivalents and Restricted Cash

The reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheet to the totals shown within the consolidated statements of cash flows is as follows (in thousands):

	2023	2022	2021
Cash and cash equivalents	$944,073	$1,315,792	$1,550,004
Restricted cash included in prepaid expenses and other current assets (1)	4,789	8,221	—
Restricted cash included in other non-current assets (1)	40,722	45,568	42,924
Total cash, cash equivalents and restricted cash	$989,584	$1,369,581	$1,592,928

(1)Includes cash balances collateralizing letters of credit associated with the Company’s facility leases and a customer prepayment requiring segregation and restrictions in its use in accordance with the customer agreement.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	As of December 31,
	2023	2022
Notes receivable (Note 4)	$12,293	$—
Prepaid expenses	10,360	18,145
Prepaid insurance and insurance recoveries	10,063	16,960
Restricted cash	4,789	8,221
Other receivables	1,546	1,561
Security deposits	318	2,084
Inventory	46	4,364
Other current assets	362	487
Prepaid expenses and other current assets	$39,777	$51,822

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following (in thousands):

	As of December 31,
	2023	2022
Lab equipment	$147,185	$183,292
Leasehold improvements	71,564	125,307
Buildings and facilities	47,034	46,019
Construction in progress	15,830	23,426
Computer equipment and software	14,780	15,219
Furniture and fixtures	6,458	8,206
Land	6,060	6,060
Total property, plant, and equipment	308,911	407,529
Less: Accumulated depreciation and amortization	(120,718)	(92,756)
Property, plant, and equipment, net	$188,193	$314,773

Depreciation and amortization expense for the years ended December 31, 2023, 2022 and 2021 totaled $54.8 million, $36.9 million and $26.9 million, respectively.

During the year ended December 31, 2023, the Company identified excess lab equipment attwo of its facilities whereby the assets were sold, classified as held for sale or otherwise impaired, resulting in aggregate impairment losses of $25.2 million, included in general and administrative expense in the consolidated statement of operations and comprehensive loss.

Other Non-Current Assets

Other non-current assets consisted of the following (in thousands):

	As of December 31,
	2023	2022
Restricted cash	$40,722	$45,568
Notes receivable (Note 4)	13,601	37,660
Finance lease right-of-use assets, net	2,230	3,256
Other assets	1,502	2,241
Other non-current assets	$58,055	$88,725

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	As of December 31,
	2023	2022
Professional fees and securities litigation costs	$27,884	$12,178
Operating lease liabilities	18,878	28,032
Contingent consideration liability	18,468	6,378
Employee compensation and benefits	15,678	19,441
Deferred other income	4,009	—
Biosecurity costs	3,564	15,401
External research and development expenses	2,739	1,844
Property and equipment	2,667	11,624
Finance lease liabilities	1,055	1,300
Lab supplies	861	3,434
Other current liabilities	14,248	15,062
Accrued expenses and other current liabilities	$110,051	$114,694

Supplemental cash flow information

The following table presents supplemental cash flow information for each reporting period (in thousands):

	Year Ended December 31,
	2023	2022	2021
Cash paid for interest	$83	$92	$2,370
Cash paid for income taxes	670	—	61
Non-cash investing and financing activities:
ROU assets obtained in exchange for new operating lease liabilities upon adoption of ASC 842	$—	$147,744	$—
ROU assets obtained in exchange for new finance lease liabilities upon adoption of ASC 842	—	3,397	—
ROU assets obtained in exchange for new operating lease liabilities	27,668	79,984	—
ROU assets obtained in exchange for new finance lease liabilities	—	1,729	—
Purchase of minority interest in Cooksonia	—	7,390	—
Purchases of equipment through capital leases	—	—	1,981
Lease financing obligation for build-to-suit lease	—	—	6,120
Purchases of property and equipment included in accounts payable and accrued expenses	2,915	12,881	1,815
Equity received in related parties	—	8,873	61,554
Convertible financial instruments received for Cell Engineering services	4,542	29,074	—
Equity securities and warrants received for Cell Engineering services	17,450	3,423	10,000
Conversion of convertible promissory notes to preferred stock	—	—	195
Non-cash consideration paid for the acquisition of Zymergen	—	231,750	—
Common stock issued for acquisitions	6,820	40,382	15,087
Acquisition date fair value of contingent consideration liability	—	19,912	8,760
Acquisition date fair value of warrant liabilities	—	—	194,453
Settlement of contingent consideration liability	8,896	—	—
Equity issuance costs in accounts payable and accrued expenses	—	578	—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.